Meeting
2020 ASCO Virtual Scientific Program
Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes.
Authors
Reva K Basho
Cedars-Sinai Medical Center, Houston, TX
Reva K Basho , Clinton Yam , Jason B White , Li Zhao , Lei Huo , Elizabeth A. Mittendorf , Alastair Mark Thompson , Jennifer Keating Litton , Banu Arun , Bora Lim , Vicente Valero , Debu Tripathy , Jianhua Zhang , Beatriz E Adrada , Lumarie Santiago , Elizabeth Ravenberg , Stacy L. Moulder , Senthil Damodaran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 561)
DOI
10.1200/JCO.2020.38.15_suppl.561
Abstract #
561
Poster Bd #
53
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide.
First Author: Bora Lim
Poster
2019 ASCO Annual Meeting
Delineating longitudinal patterns of response to neoadjuvant systemic therapy (NAST) in triple-negative breast cancer (TNBC): Profiling results from a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS; NCT02276443).
First Author: Sahil Seth
Poster
2020 ASCO Virtual Scientific Program
Germline alterations other than BRCA in triple negative breast cancer (TNBC) patients who underwent neoadjuvant therapy (NAT) on a prospective clinical trial.
First Author: Banu Arun
Poster
2018 ASCO Annual Meeting
Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes.
First Author: Reva K Basho